Ionis holder plans Rule 144 sale of 15,642 shares

Ionis Pharmaceuticals shareholder Eric Swayze has filed a notice of proposed sale of 15,642 shares of common stock under Rule 144.

Rhea-AI Filing Summary

Ionis Pharmaceuticals shareholder Eric Swayze has filed a notice of proposed sale of 15,642 shares of common stock under Rule 144. The shares, to be sold through Stifel Nicolaus & Company Inc. on Nasdaq around 02/13/2026, have an aggregate market value of $1,277,169.00. The filing notes that 161,974,393 shares of Ionis common stock were outstanding. These 15,642 shares were acquired on 01/15/2026 as restricted stock units granted by the issuer as equity compensation. Over the prior three months, Swayze sold additional Ionis common stock in three transactions totaling 39,526 shares for gross proceeds of $3,122, - combining reported amounts of $1,853,577.00, $753,501.00, and $512,906.00.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What does the Form 144 filing for Ionis (IONS) disclose?

The Form 144 discloses a planned resale of Ionis common stock. Shareholder Eric Swayze filed to sell 15,642 Ionis common shares under Rule 144 through Stifel Nicolaus on Nasdaq, providing details on acquisition, market value, and recent sales history over the prior three months.

How many Ionis (IONS) shares is Eric Swayze planning to sell?

Eric Swayze plans to sell 15,642 Ionis common shares. The filing lists these shares in the Securities Information table with an aggregate market value of $1,277,169.00 and identifies Stifel Nicolaus & Company Inc. as the broker handling the planned Nasdaq transaction.

What is the aggregate market value of Ionis (IONS) shares in this Form 144?

The planned 15,642-share sale has an aggregate market value of $1,277,169.00. This value is shown in the Securities Information section alongside the number of shares to be sold, the broker Stifel Nicolaus, and the Nasdaq listing.

When were the Ionis (IONS) shares in the Form 144 acquired and how?

The 15,642 shares were acquired on 01/15/2026 via restricted stock units. The Securities To Be Sold table states they were obtained from the issuer as equity compensation, with the same date listed for acquisition and payment.

What recent Ionis (IONS) stock sales has Eric Swayze reported in the last 3 months?

The filing lists three prior Ionis stock sales in the past three months. On 01/02/2026 he sold 23,463 shares for $1,853,577.00, on 01/16/2026 sold 9,884 shares for $753,501.00, and on 01/30/2026 sold 6,179 shares for $512,906.00.

How many Ionis (IONS) shares were outstanding according to the Form 144?

The filing reports 161,974,393 Ionis common shares outstanding. This figure appears in the Securities Information table as the number of shares or other units outstanding, providing context for the planned 15,642-share Rule 144 sale.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 02/13/2026 - 04:04 PM Learn about SEC filing dates

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK	0001791058
Filer CCC	XXXXXXXX
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer	IONIS PHARMACEUTICALS INC
SEC File Number	000-19125
Address of Issuer	2855 GAZELLE COURT CARLSBAD CALIFORNIA 92010
Phone	7609319200
Name of Person for Whose Account the Securities are To Be Sold	Swayze Eric
See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.
Relationship to Issuer	Officer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common Stock	Stifel Nicolaus & Company Inc 501 N Broadway St. Louis MO 63102	15642	1277169.00	161974393	02/13/2026	Nasdaq

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common Stock	01/15/2026	Restricted Stock Units	Issuer			15642	01/15/2026	Equity Compensation

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
Eric Swayze 2855 Gazelle Ct Carlsbad CA 92010	Common Stock	01/02/2026	23463	1853577.00
Eric Swayze 2855 Gazelle Ct Carlsbad CA 92010	Common Stock	01/16/2026	9884	753501.00
Eric Swayze 2855 Gazelle Ct Carlsbad CA 92010	Common Stock	01/30/2026	6179	512906.00

144: Remarks and Signature

Remarks
Date of Notice	02/13/2026
Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1	08/14/2024
ATTENTION:
The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
Signature	/s/ Luca Lotito, as a duly authorized representative of STIFEL, as attorney-in-fact for Eric Swayze
ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)